New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 10, 2014
13:50 EDTBIOS, VICL, IPCI, ALIM, CBMXVical, CombiMatrix poised for breakouts, says
In a report on stocks with technical attributes that indicate they may be poised for a near-term breakout, TheStreet's Roberto Pedone identifies CombiMatrix (CBMX), Vical (VICL), Intellipharmaceutics (IPCI), BioScrip (BIOS) and Alimera Sciences (ALIM). Reference Link
News For VICL;CBMX;IPCI;BIOS;ALIM From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 25, 2014
07:29 EDTBIOSBioScrip management to meet with SunTrust
Meetings to be held in Boston on December 2 and in New York on December 3 hosted by SunTrust.
November 24, 2014
07:33 EDTIPCIBrean Capital to hold a summit
Subscribe for More Information
November 20, 2014
08:17 EDTBIOSBioScrip initiated with an Outperform at Barrington
Subscribe for More Information
07:42 EDTIPCIIntellipharmaceutics notes launch of 5mg strength Focalin XR by Teva
Subscribe for More Information
November 18, 2014
07:35 EDTIPCIIntellipharmaceutics appoints Domenic Della Penna as CFO
Subscribe for More Information
November 17, 2014
11:46 EDTALIMAlimera Sciences' ILUVIEN receives marketing approval in Ireland
Subscribe for More Information
10:02 EDTALIMOn The Fly: Analyst Initiation Summary
Subscribe for More Information
08:55 EDTALIMAlimera Sciences initiated with a Buy at Summer Street
Target $12.
November 12, 2014
07:43 EDTALIMAlimera Sciences' Iluvien receives marketing authorization in Belgium
Alimera Sciences,announced that the Belgian Federal Agency for Medicines and Health Products has granted marketing authorization to ILUVIEN for the treatment of vision impairment associated with chronic diabetic macular edema considered insufficiently responsive to available therapies. Approval in Belgium marks the fourth European approval through the Repeat-Use application procedure and the 12th approval worldwide, including the recent U.S. approval for the treatment of DME in patients who have been previously treated with a course of corticosteroids and did not have a clinically significant rise in intraocular pressure. To date, ILUVIEN is now approved for marketing in Austria, Belgium, Denmark, France, Germany, Italy, Norway, Portugal, Spain, Sweden, the United Kingdom and the United States, and is commercially available in the United Kingdom and Germany. ILUVIEN is pending approval in an additional six European Union countries included in the Repeat-Use application procedure. These countries are the Czech Republic, Finland, Ireland, Luxembourg, the Netherlands and Poland.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use